Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 58c
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $243.71 -2.78%
Revenue Growth %: +7.1%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +7.1%
Financial Fact:
Total revenues: 374.18M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.21, $0.58 better than the analyst estimate of $3.63. Revenue for the quarter came in at $892.88 million versus the consensus estimate of $865.88 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2022 EPS of $16.00-$17.00, versus the consensus of $17.47.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue
- MongoDB stock tumbles despite earnings beat on profit-taking
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
